Achieve Life Sciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ACHV Nasdaq 2830 www.achievelifesciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Achieve Life Sciences, Inc.

ACHV: 2Q:25 NDA Submission - Mar 12th, 2025 9:45 am
Q4 2024 Achieve Life Sciences Inc Earnings Call - Mar 12th, 2025 7:14 am
Achieve Life Sciences Inc (ACHV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Mar 12th, 2025 7:02 am
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program - Mar 11th, 2025 11:30 am
Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference - Mar 7th, 2025 1:30 pm
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025 - Mar 6th, 2025 1:30 pm
Here are Rogue Funds Updates on Achieve Life Sciences (ACHV) - Feb 18th, 2025 12:29 pm
Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference - Feb 11th, 2025 1:30 pm
Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial - Feb 10th, 2025 1:30 pm
Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory - Jan 24th, 2025 5:14 pm
ACHV: Long-Term Exposure Requirement Complete - Jan 21st, 2025 9:58 am
Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors - Jan 10th, 2025 1:30 pm
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission - Jan 7th, 2025 1:30 pm
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week - Jan 6th, 2025 1:30 pm
Should You Expect a Strong Re-rating for Achieve Life Sciences (ACHV) Post Results in Q1? - Jan 2nd, 2025 4:04 pm
Institutional shareholders may be less affected by Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) pullback last week after a year of 0.5% returns - Dec 22nd, 2024 2:45 pm
Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer - Dec 9th, 2024 1:30 pm
Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA - Dec 3rd, 2024 1:30 pm
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences - Nov 14th, 2024 1:30 pm
ACHV: Commercialization in Focus - Nov 11th, 2024 8:00 am